biotech stocks to buy or sell

Biotech stocks and the biotech sector have proven to be one of the fastest-growing sectors over the last decade. According to most experts, it is expected to continue in the same vein in the foreseeable future.

It’s important for investors to have some coverage for biotech stocks in their portfolios and watch the market closely for the best opportunities. Having a look at recent moves is a great way to go about it. Here is a look at 3 biotech stocks to watch in September.

Pharmacyte Biotech (PMCB)

A Few weeks ago, PharmaCyte Biotech (PMCB) announced that nationally and internationally renowned clinician and oncologist, Dr. Manuel Hidalgo, has confirmed that he will be Principal Investigator for PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer now that he is at Weill Cornell Medical Center.

Dr. Hidalgo, a leading physician-scientist who specializes in pancreatic cancer and drug development, was recently appointed Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center. Previously, Dr. Hidalgo was a Professor of Medicine at the Harvard Medical School and the Chief of the Division of Hematology-Oncology and Director of the Rosenberg Clinical Cancer Center at the Beth Israel Deaconess Medical Center.

Right now, PharmaCyte (PMCB) could be on the verge of a major FDA event. This industry is experiencing remarkable innovation, and now the race is to get behind the next breakthrough. Its drug delivery technology could change the way countless diseases are treated. It starts with a “box.” Cell In A Box ® technology specifically, can be used as a platform upon which therapies for several types of cancer and even diabetes are being developed.

Essentially, PharmaCyte’s (PMCB) therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. This could mean that they’ve found a way to take a broad treatment (chemotherapy) and turn it into a targeted one…Continue Reading About PharmaCyte’s Breakthrough Technology

Arrowhead Pharmaceuticals (ARWR)

One of the biotech stocks that made significant gains in August was that of Arrowhead Pharmaceuticals Inc (ARWR Stock Report). The biggest trigger behind the surge in the stock price was the company’s better than expected performance in the nine months of fiscal 2019. Considering the fact that Arrowhead is not fully commercial yet, the performance caused enough excitement in the market and the stock surged by more than 17% in the month of August.

biotech stocks to watch ARWR stock

The primary reason behind the impressive growth was the company’s developmental partnership with Johnson & Johnson. By virtue of that contract alone, Arrowhead was able to bring in as much as $51.5 million in operating profits during that period. It is a stock that is definitely worth keeping in the watch list.

Adaptive Biotechnologies (ADPT)

However, Arrowhead was comfortably bypassed in August by the Adaptive Biotechnologies Corp (ADPT Stock Report) stock. ADPT which experienced a surge of almost 32% in the month. The company is involved in the diagnostics space. Although it has recently had its IPO, it managed to generate impressive growth in Q2 2019.

biotech stocks to watch ADPT

Revenues grew significantly both in the second quarter and the first half of 2019. Adaptive also reduced its operating losses. This triggered a lot of optimism among investors. As a result, ADPT stock climbed steadily through the course of last month. What will come next?

biotech stocks to buy or sell
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 9/12/2019. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

What’s Next For The Real Estate Industry?

The coronavirus economic shock has left some questioning the stock market. But…

International Land Alliance (ILAL) Announces Affordable Option at Bajamar

SAN DIEGO, CALIFORNIA, April 27, 2020 (GLOBE NEWSWIRE) — International Land Alliance,…

Multi-Trillion Dollar Industry Providing Massive Opportunity in 2019 & Beyond

The most recent global report from the United Nations states that by …